Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xilio Therapeutics (XLO) Income from Continuing Operations (2024 - 2025)

Historic Income from Continuing Operations for Xilio Therapeutics (XLO) over the last 2 years, with Q3 2025 value amounting to -$1.9 million.

  • Xilio Therapeutics' Income from Continuing Operations rose 8693.27% to -$1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.8 million, marking a year-over-year change of. This contributed to the annual value of -$60.6 million for FY2024, which is N/A changed from last year.
  • Per Xilio Therapeutics' latest filing, its Income from Continuing Operations stood at -$1.9 million for Q3 2025, which was up 8693.27% from -$14.4 million recorded in Q2 2025.
  • In the past 5 years, Xilio Therapeutics' Income from Continuing Operations ranged from a high of -$1.9 million in Q3 2025 and a low of -$14.8 million during Q3 2024